Scutellaria Lateriflora Whole

Dosage for Scutellaria Lateriflora Whole is not standardized and must be individualized based on the patient's sensitivity and clinical response.

• Diagnostic Testing: For skin prick testing, a single drop of a 1:10 or 1:20 w/v (weight/volume) concentration is typically applied. For intradermal testing, 0.02 mL to 0.05 mL of a highly diluted extract (e.g., 1:1000 or 1:10,000) is injected.
• Immunotherapy (Maintenance): The dose is gradually increased from a very low starting point. A typical maintenance dose may range from 0.1 mL to 0.5 mL of the most concentrated solution tolerated by the patient, usually administered once every 1 to 4 weeks.

Scutellaria Lateriflora Whole is used in children, but dosage must be calculated with extreme caution. Pediatric patients are often more sensitive to allergenic extracts. Dosing follows the same titration principle as adults but often starts at even higher dilutions. Clinical studies have shown that immunotherapy is generally safe for children aged 5 and older, but its use in younger children must be carefully weighed by a pediatric allergist.

Renal Impairment

No specific dosage adjustments are provided for renal impairment; however, because metabolites are cleared renally, patients with Stage 4 or 5 chronic kidney disease should be monitored closely for systemic reactions.

Hepatic Impairment

Patients with severe liver disease may have altered metabolism of the flavonoid components of the extract. Caution is advised, though no formal dose-reduction protocols exist.

Elderly Patients

Geriatric patients (65+) should be assessed for underlying cardiovascular disease before administration. The risk of adverse reactions to epinephrine (used to treat potential anaphylaxis) must be considered when determining the dose of the extract.

This medication is never for self-administration at home. It must be administered by a healthcare professional in a clinic equipped with emergency resuscitation equipment.

• Administration Route: Subcutaneous injection (for immunotherapy) or epicutaneous/intradermal (for testing).
• Preparation: The vial should be inspected for particulate matter or discoloration. It should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F).
• Observation: Patients must remain in the clinic for at least 30 minutes following an injection to monitor for signs of a systemic allergic reaction.

If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.

• < 1 week late: Continue with the scheduled dose.
• 1-2 weeks late: Maintain the previous dose level.
• > 3 weeks late: The dose may need to be reduced by one or more increments to prevent a systemic reaction.

An overdose of Scutellaria Lateriflora Whole can lead to a severe systemic allergic reaction or anaphylactic shock.

• Signs of Overdose: Rapid heart rate, difficulty breathing, widespread hives, swelling of the throat, or a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and IV fluids. Seek emergency medical attention immediately if these symptoms occur outside a clinical setting.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or frequency without medical guidance.

Most patients receiving Scutellaria Lateriflora Whole will experience local reactions at the site of administration. These are generally considered normal and indicate the body is responding to the allergen.

• Injection Site Redness (Erythema): A red patch around the injection site that may appear within minutes and last for several hours.
• Local Swelling (Wheal): A raised, itchy bump at the site of the injection or skin test. This typically resolves within 24 hours.
• Pruritus (Itching): Intense itching at the site of administration.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter, which may cause discomfort or stiffness in the arm.
• Fatigue: A general feeling of tiredness or lethargy following an immunotherapy session.
• Headache: Mild to moderate tension-type headaches.

• Generalized Urticaria: Hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site.

> Warning: Stop taking Scutellaria Lateriflora Whole and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening allergic reaction characterized by a sudden drop in blood pressure, fainting, and multi-organ involvement.
• Bronchospasm: Tightening of the muscles lining the airways, causing severe wheezing and shortness of breath.
• Laryngeal Edema: Swelling of the throat or larynx, leading to a 'closing' sensation and difficulty swallowing.
• Hypotension: A dangerous drop in blood pressure that may cause dizziness or loss of consciousness.
• Cardiac Arrhythmia: Irregular heartbeats, which may be exacerbated by the adrenergic properties of the extract.

Prolonged use of Scutellaria Lateriflora Whole in immunotherapy is generally well-tolerated. However, some patients may develop a persistent sensitivity or 'delayed-phase' reactions, where swelling and redness appear 6 to 12 hours after the injection. There is no evidence that long-term use causes organ toxicity, provided that systemic reactions are avoided.

While Scutellaria Lateriflora Whole may not have a specific individual black box warning for the 'Scutellaria' component alone, all non-standardized allergenic extracts carry a general class warning regarding Anaphylaxis.

Summary of Warning: This product can cause severe life-threatening systemic reactions, including anaphylactic shock. It should only be administered by physicians who are exceptionally experienced in the treatment of anaphylaxis and the management of respiratory emergencies. Patients with unstable asthma are at a significantly higher risk for fatal reactions.

Report any unusual symptoms or persistent site reactions to your healthcare provider immediately.

Scutellaria Lateriflora Whole is a potent biological agent. Its use is restricted to diagnostic and therapeutic immunological procedures. It is not for self-administration. Patients must be screened for any underlying conditions that could make an allergic reaction more dangerous, such as severe cardiovascular disease or poorly controlled asthma.

No specific FDA black box warning exists for Scutellaria Lateriflora Whole as a standalone entity, but it falls under the mandatory class warnings for Allergenic Extracts. These warnings emphasize that the extract should only be used in settings where emergency resuscitative equipment and personnel are immediately available. Fatalities have occurred with the use of allergenic extracts when administered to patients with severe asthma or when dosing errors occurred.

• Allergic Reactions / Anaphylaxis Risk: This is the primary risk. Patients must be monitored for at least 30 minutes post-injection. The risk is higher during the 'build-up' phase of immunotherapy.
• Asthma Status: Patients experiencing an asthma flare-up or who have a Forced Expiratory Volume (FEV1) of less than 70% of predicted values should not receive an injection until their asthma is stabilized.
• Adrenergic Activity: Because the extract has alpha and beta-adrenergic agonist properties, it may interact with blood pressure medications or exacerbate certain heart conditions.
• Nitrogen Binding: Patients with urea cycle disorders or those on nitrogen-restricted diets should discuss the 'Nitrogen Binding Agent' classification with their specialist.

• Peak Flow Meter: Asthma patients should check their lung function before each injection.
• Vital Signs: Blood pressure and heart rate may be monitored if the patient has a history of cardiovascular sensitivity.
• Site Observation: The healthcare provider will measure the size of any wheal or flare reaction to determine the safety of the next dose.

Patients should avoid driving or operating heavy machinery for at least 30 minutes after receiving an injection, as a systemic reaction could cause sudden dizziness, fainting, or visual disturbances.

Alcohol should be avoided on the day of an injection. Alcohol can increase blood flow to the skin and potentially accelerate the absorption of the allergen, increasing the risk of a systemic reaction. It can also mask the early symptoms of anaphylaxis.

If a patient experiences a severe systemic reaction, the healthcare provider may decide to discontinue Scutellaria Lateriflora Whole immunotherapy permanently or significantly reduce the dose. There are no withdrawal symptoms associated with stopping allergenic extracts, but the patient's allergy symptoms may return.

> Important: Discuss all your medical conditions, especially respiratory or heart problems, with your healthcare provider before starting Scutellaria Lateriflora Whole.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are strictly contraindicated or used with extreme caution in patients receiving allergenic extracts. Beta-blockers can make an allergic reaction more severe and, more importantly, they can make epinephrine (the treatment for anaphylaxis) ineffective. This can lead to fatal outcomes during an emergency.

• ACE Inhibitors (e.g., Lisinopril): These may increase the risk of systemic reactions or more severe hypotension during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): Due to the adrenergic agonist properties of Scutellaria Lateriflora Whole, use with MAOIs may lead to an exaggerated increase in blood pressure (hypertensive crisis).
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs can potentiate the effects of adrenergic agents, increasing the risk of cardiac arrhythmias.

• Other Allergenic Extracts: Taking multiple types of allergy shots simultaneously can increase the total 'allergic load' on the immune system, making a reaction more likely.
• Immunosuppressants (e.g., Prednisone, Cyclosporine): These medications may reduce the effectiveness of diagnostic skin testing (causing false negatives) and may decrease the efficacy of immunotherapy.

• High-Nitrogen Foods: Given the ammonium ion binding activity, the clinical significance of high-protein diets is unknown but should be discussed with a doctor.
• Caffeine: May exacerbate the adrenergic (stimulant) effects of the extract, leading to jitters or increased heart rate.

• St. John's Wort: May alter the metabolism of the flavonoid components via CYP3A4 induction.
• Kava Kava / Valerian: Since Scutellaria is traditionally used as a sedative, combining it with other herbal sedatives may cause excessive drowsiness.
• Ephedra / Ma Huang: Combining with other adrenergic herbs significantly increases cardiovascular risk.

• Skin Test Suppression: Antihistamines (H1 blockers like Claritin or Benadryl) must be stopped 3-7 days before skin testing, as they will prevent the 'wheal and flare' reaction, leading to false-negative results.
• Tryptase Levels: If a systemic reaction occurs, a serum tryptase test may be performed to confirm mast cell degranulation.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy pills.

• Severe, Uncontrolled Asthma: Patients with an FEV1 persistently below 70% of predicted values are at high risk for fatal bronchospasm during immunotherapy.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The stress of a potential systemic reaction or the administration of epinephrine could be fatal.
• Hypersensitivity to Extract Components: Any known previous anaphylactic reaction to Scutellaria or the preservatives used in the extract (such as phenol or glycerin).
• Beta-Blocker Therapy: As noted, the inability to respond to epinephrine makes immunotherapy unacceptably dangerous.

• Autoimmune Disorders: Patients with active systemic lupus erythematosus (SLE) or rheumatoid arthritis may experience a flare-up of their condition as the immune system is stimulated.
• Malignancy: Patients with active cancer may have altered immune responses.
• Pregnancy (Initiation): While maintenance immunotherapy is often continued, starting a new, higher-risk build-up phase during pregnancy is generally avoided.

Patients allergic to other members of the Lamiaceae family (Mint, Basil, Oregano, Rosemary, Sage, Lavender) may show cross-reactivity to Scutellaria Lateriflora Whole. A positive skin test for one may indicate a potential reaction to the others.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and current medications, before prescribing Scutellaria Lateriflora Whole.

Pregnancy Category C: Animal reproduction studies have not been conducted with Scutellaria Lateriflora Whole. It is not known whether the extract can cause fetal harm or affect reproduction capacity.

• Risk-Benefit: Immunotherapy is generally not started during pregnancy due to the risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen). However, if a patient is already on a maintenance dose and tolerating it well, the doctor may choose to continue the treatment at the same or a reduced dose.

It is not known whether the components of Scutellaria Lateriflora Whole are excreted in human milk. Because many botanical flavonoids and proteins can pass into milk, caution should be exercised. The risk of the infant developing a sensitivity or having a reaction is low but theoretically possible. Most experts consider immunotherapy compatible with breastfeeding.

Scutellaria Lateriflora Whole is used in children for allergy diagnosis and treatment. However, the safety and effectiveness in children under the age of 5 have not been established. Children must be able to communicate symptoms of an impending systemic reaction (e.g., itchy throat, 'funny' feeling) for the treatment to be administered safely.

Clinical studies of allergenic extracts often do not include sufficient numbers of subjects aged 65 and over. In elderly patients, the risk of cardiovascular complications from a systemic reaction is higher. Doctors must carefully evaluate the patient's heart health and their ability to tolerate emergency epinephrine before starting treatment.

There is no specific data on patients with renal impairment. However, since the kidneys are involved in the excretion of botanical metabolites, a conservative approach to dosing is recommended for patients with a GFR below 30 mL/min.

In patients with Child-Pugh Class B or C hepatic impairment, the metabolism of the flavonoids in Scutellaria (like baicalin) may be slowed. While this does not usually affect the immediate allergic response, it may increase the risk of secondary side effects like fatigue or headache.

> Important: Special populations require individualized medical assessment and often more frequent monitoring during the initial phases of treatment.

Scutellaria Lateriflora Whole acts as an exogenous antigen. Upon administration, it cross-links IgE antibodies on the surface of mast cells and basophils. This triggers a signal transduction cascade involving tyrosine kinases, leading to the release of pre-formed mediators (histamine, tryptase) and the synthesis of newly formed mediators (leukotrienes, prostaglandins). In immunotherapy, repeated exposure to increasing doses of the extract induces a shift in the T-cell response from a Th2 (allergic) profile to a Th1 (non-allergic) profile, increases the production of Regulatory T-cells (Tregs), and stimulates the production of IgG4 'blocking' antibodies.

The specific Ammonium Ion Binding Activity and Adrenergic Agonist properties suggest that components of the whole plant (likely the alkaloids and flavonoids) interact with metabolic pathways and the autonomic nervous system, though these are secondary to its primary immunological function.

• Onset of Action (Testing): 15-20 minutes for a wheal and flare reaction.
• Onset of Action (Therapy): 6-12 months of consistent immunotherapy are usually required to see a reduction in allergy symptoms.
• Duration of Effect: The diagnostic skin reaction lasts 2-4 hours. The immunological changes from immunotherapy can persist for years after the treatment is completed.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous), Negligible (Prick) |

| Protein Binding | Variable (components bind to albumin) |

| Half-life | 4-12 hours (metabolites) |

| Tmax | 1-2 hours (systemic absorption post-injection) |

| Metabolism | Hepatic (Flavonoids), Proteolytic (Proteins) |

| Excretion | Renal (>80%), Fecal (<20%) |

• Molecular Formula: Complex mixture (contains C21H18O12 - Scutellarin as a marker).
• Molecular Weight: Varies by component (Scutellarin: 462.36 g/mol).
• Solubility: Soluble in water and aqueous buffers; partially soluble in glycerin.
• Structure: A complex botanical matrix consisting of flavonoids (baicalin, scutellarin), volatile oils, tannins, and allergenic proteins.

Scutellaria Lateriflora Whole is classified as a Non-Standardized Biological Allergenic Extract. It is related to other plant extracts like Ambrosia artemisiifolia (Ragweed) and Phleum pratense (Timothy Grass), although its specific chemical profile as a 'Nitrogen Binding Agent' and 'Adrenergic Agonist' is unique among common allergens.